Clinical Trial Update: Managed Access Programs for ETB115, Eltrombopag

View source ↗

Summary

Novartis reports that managed access programs for ETB115, the eltrombopag product, are available for treating thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Eltrombopag (ETB115) (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thrombocytopenia | Status: AVAILABLE